心脏M3受体作为抗心律失常药物新靶点研究的进展

心脏在交感神经和副交感神经的精细控制下完成正常的生理功能，心脏迷走神经通过刺激M型乙酰胆碱受体（muscarinic acetylcholine receptor．mAchR）调节心脏收缩力、兴奋性和传导。目前，通过分子生物学技术已经克隆出哺乳动物M受体的5个亚型，即m1，m2，m3，m4和m5。由于尚无m5受体相对特异性阻滞剂和激动剂，通过药理学的方法，将M受体分为M1，M2，M3及M4等4个亚型。     

抗心律失常药物作用的新靶点--M3-R/IKM3

目的　研究心脏M3受体 /M3受体介导的钾通道与心律失常的关系,寻找抗心律失常药物的新靶点。方法分别以结扎大鼠左冠状动脉前降支所致急性心律失常模型和膜片钳技术为基础,观察M3受体的干预作用及作用机制。结果　M3受体阻断剂 4DAMP(4 diphenylacetoxy N methylpiperidine methiodide)加重结扎大鼠冠状动脉前降支所致心律失常,而M3受体激动剂胆碱能明显对抗其作用。其他亚型受体阻断剂,M1受体阻断剂 (prienzepine)、M2受体阻断剂(methotramine)和M4受体阻断剂 (tropicamide)对结扎大鼠左冠状动脉前降支所致急性心律失常无影响。在膜片钳实验中发现,胆碱可激活一种延迟整流钾电流(IKM3 ),此电流可被M3受体阻断剂 4DAMP明显抑制。而M1,M2和M4受体阻断剂对胆碱介导的电流无作用。结论　胆碱通过激动心肌M3受体诱发一外向钾电流 (IKM3 ),并在维持心脏离子通道平衡中起重要作用。M3受体 /IKM 可能是抗心律失常新靶点。     

M3受体在脑心综合征心律失常中的作用

观察M₃受体(M₃R)在脑心综合征(CCS)模型大鼠心室肌中的作用及其表达，以探讨其与CCS心律失常的关系。线栓法建立CCS模型，监测心电图，激光共聚焦扫描显微镜记录激动M₃R后心肌细胞内钙的变化，Western blotting检测心室肌中M₃R表达水平的改变。同对照组相比，模型组心电图QRS、QT间期显著延长(P<0.01)；Western blotting结果显示模型组心室肌中M₃R的表达水平较对照组显著降低(P<0.05)；胆碱激动M₃R可以抑制KCl除极诱导的模型组心肌细胞内钙的升高幅度(P<0.01)，其特异阻断剂4-DAMP可以阻断这一作用。M₃R表达降低可能是CCS心律失常的重要原因之一。激动M₃R可以降低心肌细胞内钙，M₃R可能是治疗CCS心律失常新的靶点。     

M3受体与大鼠缺血性心肌细胞凋亡关系的研究M3受体与大鼠缺血性心肌细胞凋亡关系的研究

目的观察M₃受体对大鼠缺血性心肌细胞凋亡的作用及其机制。方法结扎大鼠左冠状动脉前降支建立急性心肌缺血模型,给予M₃受体激动剂胆碱或阻断剂4DAMP进行干预,观察M₃受体对其的影响。结果缺血前15 min iv胆碱10 mg·kg^-1可提高血清超氧化物歧化酶(SOD)活力,降低丙二醛(MDA)含量,减少凋亡细胞的数量(P<0.01),并可增加Bcl-2表达,减少Fas表达。预先5 min iv 4DAMP 0.12 mg·kg^-1阻断心肌M₃受体可逆转胆碱的作用。结论激动M₃受体对结扎大鼠冠状动脉诱导的心肌损伤有保护作用,其机制可能与调节Bcl-2和Fas表达从而抑制心肌细胞凋亡有关。     

M3受体对体外H2O2诱导大鼠心肌细胞凋亡的保护作用

目的探讨M₃受体激动对H₂O₂诱导的大鼠培养心肌细胞凋亡的作用，进一步阐明其机制。方法末端标记法 (TUNEL)进行细胞凋亡检测；免疫组化方法检测Bcl-2和Fas的表达；共聚焦显微镜观察［Ca²⁺］_i荧光强度变化。结果M₃受体激动剂胆碱(10 mmol·L^-1)可减少H₂O₂诱导的心肌细胞凋亡的数量，并可增加心肌Bcl-2的表达，减少Fas表达，抑制H₂O₂诱导的［Ca²⁺］_i荧光强度的升高。但预先应用4DAMP (10 nmol·L^-1)阻断M₃受体可逆转胆碱作用。结论激动M₃受体对H₂O₂诱导的心肌细胞凋亡有保护作用，其机制可能与Bcl-2和Fas表达以及下调［Ca²⁺］_i有关。     

抗心律失常药物作用的靶点——HERG K+通道

快速延迟整流钾电流(rapidly activating component of delayed rectifier potassium current，I_Kr)在心肌动作电位复极化过程中发挥重要作用。HERG基因编码心脏快速延迟整流钾通道的α亚基，HERG基因突变导致遗传性长QT间期综合征(long QT syndrome，LQTS)，另外I_Kr/HERG通道是绝大多数能引起心脏QT间期延长药物的作用靶标，其他一些化学结构不同的药物也可阻断该通道，引起QT间期延长，甚至发展成获得性心律失常。本文从门控机制及功能、HERG通道相关的心律失常、药物与通道相互作用机制、优化通道靶点的策略等四个方面综述I_Kr/HERG通道在抗心律失常方面的最新研究进展。     

白藜芦醇能够修复离体缺血再灌注损伤大鼠心脏M3受体与间隙连接蛋白43间结构及功能性整合

为了探讨白藜芦醇是否能通过影响M₃受体和间隙连接蛋白43(Cx43)间结构及功能性整合发挥其抗心肌缺血再灌注损伤作用，应用免疫共沉淀、免疫印迹及免疫荧光技术研究白藜芦醇对M₃受体与Cx43间结构及功能性整合的影响。结合大鼠离体II导联心电图及心肌超氧化物歧化酶(SOD)、丙二醛(MDA)的检测观察白藜芦醇是否能恢复心肌缺血再灌注损伤。白藜芦醇能修复心肌缺血再灌注损伤所致的M₃受体与Cx43间结构及功能性整合的破坏及纠正Cx43表达异常。同时QRS波时限﹑SOD及MDA的改变也得到相应恢复。白藜芦醇能修复M₃受体与Cx43间结构及功能性整合而发挥抗缺血再灌注损伤作用。     

苯妥英钠与前列腺素E2联合应用抗实验性哇巴因心律失常的研究

关于联合用药治疗心律失常,目前报道甚少,对此问题深入地进行基础理论或临床治疗学的研究,具有实际意义。已知苯妥英钠(DPH)为治疗洋地黄心律失常的有效药物。近年来亦发现前列腺素E(PGE)有抗哇巴因心律失常的作用,但其机制待深入探讨。一般认为洋地黄心律失常与交感神经活动增强有关,并发现洋地黄致心律失常时心肌儿茶酚胺含量     

M3受体作为防治心血管疾病新靶点的研究进展

心血管疾病因其具有高发病率和死亡率的特点,严重威胁着人类的健康。人们一直在致力于对心血管疾病的研究,期望可以找到更有效的治疗方法。在心脏上发现存在功能性毒蕈碱型乙酰胆碱受体(muscarinic acetylcholine receptor,m Ach R,M受体)中的M3受体后,M3受体便成为了研究心血管疾病的新领域。而随着研究的深入进行,人们发现M3受体对多种心血管疾病具有保护作用,这也使M3受体有望成为治疗心血管疾病的新靶点。本综述围绕M3受体,主要从其在心脏上的功能、对心血管疾病的影响以及其机制等方面进行阐述,期望能对今后M3受体相关疾病的研究起到支持、借鉴和鼓励作用。     

反相高效液相色谱分析赤霉素GA3含量

以μBondapak C₁₈柱建立了赤霉素GA₃的HPLC分析方法。反相HPLC梯度条件可使GA₃与包括双键异构体GA₁在内的其它同系物通过离子配对机制获得分离。此法操作简便,不需衍生化;分析快速,色谱全程仅15 min;检测灵敏,0.5μg即可准确定量;线性(r=0.999,n=5)、重复性(RSD<2%,n=4)均佳;结果准确。优越性全面超出各传统分析方法,可望成为赤霉素质量分析的标准方法。     

Site-directed mutagenesis of the putative human muscarinic M2 receptor binding site

Experimental probing of the model of the muscarinic M₂ receptor binding site proposed by Hibert et al. [Hibert, M.F., Trumpp-Kallmeyer, S., Bruinsvels, A., Hoflak, K., 1991. Three-dimensional models of neurotransmitter G-binding protein-coupled receptors. Mol. Pharmacol. 40, 8–15.] was achieved by mutating each amino-acid proposed to interact with muscarinic ligands. Pharmacological analysis of the different mutant receptors transiently expressed in human embryonic kidney (HEK/293) cells was performed with a variety of agonists and antagonists. D103A, Y403A and N404A mutations prevented binding of [³H] N-methylscopolamine and [³H] quinuclidinyl benzilate with a reduction in affinity greater than 100-fold, indicating essential contributions of these residues to the binding site for the radioligands. W400A and W155A mutations had very large effects on the binding of [³H] N-methylscopolamine (150-fold, 960-fold) but modest effects on the binding of [³H] quinuclidinyl benzilate (4-fold, 17-fold). In addition, binding of oxotremorine-M, oxotremorine, arecoline and pilocarpine to W155A resulted in a greater than 100-fold decrease in affinity. Threonine mutations (T187A and T190A) alter binding of most agonists but not of antagonists. W99 makes little contribution (<10-fold) to the binding site of the M₂ receptor. D103, W155, W400, Y403 and N404 are likely to be part of the binding site for N-methylscopolamine and also to contribute to the binding site for quinuclidinyl benzilate. Some of the predicted residues do not seem to be part of the M₂ receptor binding site but W155 is important for proper ligand binding on the muscarinic M₂ receptor, as predicted by the proposed model.     

Role of M<Subscript>3</Subscript> receptor in aconitine/barium-chloride-induced preconditioning against arrhythmias in rats

We demonstrated here that an initial treatment with aconitine- or barium-chloride-induced arrhythmias and resulted in reduced susceptibility of the heart to the induction of arrhythmias by a repeated drug treatment 24 h after the initial one, a delayed preconditioning cardioprotection. This delayed preconditioning was accompanied by enhanced expression of cardiac muscarinic M₃ receptor and abolished by M₃-selective antagonist. We conclude that muscarinic M₃ receptors might play an important role in conferring the pharmacological preconditioning against arrhythmias. This study thus expands our understanding of the cellular function and pathophysiological roles of muscarinic M₃ receptor and reconsolidates our view of cardioprotective effects of muscarinic M₃ receptor on myocardium. Yan Liu and Juan Du made equal contribution to this study.     

Investigating the interaction of McN-A-343 with the M2 muscarinic receptor using its nitrogen mustard derivative

We investigated whether the aziridinium ion formed from a nitrogen mustard derivative (4-[(2-bromoethyl)methyl-amino]-2-butynyl N-(3-chlorophenyl)carbamate; BR384) structurally related to McN-A-343 (4-(trimethyl-amino)-2-butynyl N-(3-chlorophenyl)carbamate) interacts allosterically or orthosterically with the M₂ muscarinic receptor. Chinese hamster ovary cells expressing the human M₂ muscarinic receptor were incubated with the aziridinium ion of BR384 in combination with McN-A-343 or other known orthosteric and allosteric ligands for various incubation times. After removing unreacted ligands, we measured the binding of [³H]N-methylscopolamine to residual unalkylated receptors. Affinity constants, rate constants for alkylation, and cooperativity constants were estimated for the interacting ligands using a mathematical model. Receptor alkylation by BR384 was consistent with a two-step process. After rapidly equilibrating with the receptor (step one), the aziridinium ion-receptor complex became covalently linked with a first order rate constant of about 0.95 min⁻¹ (step two). McN-A-343, acetylcholine and N-methylscopolamine competitively protected the M₂ receptor from irreversible alkylation by BR384. In contrast, the allosteric modulators, gallamine and WIN 51,708 (17-β-hydroxy-17-α-ethynyl-5-α-androstano[3,2-β]pyrimido[1,2-α]benzimidazole), allosterically inhibited or had no effect on, respectively, receptor alkylation by BR384. There was good agreement between affinity constants estimated from the kinetics of receptor alkylation and by displacement of [³H]N-methylscopolamine binding. Our results suggest that BR384 covalently binds to the orthosteric site of the M₂ receptor and that McN-A-343 binds reversibly at the same locus. Our method of analyzing allosteric interactions does not suffer from the limitations of more conventional approaches and can be adapted to detect allosteric interactions at receptors other than the muscarinic subtypes.     

Physiological roles of the melanocortin MC3 receptor

The melanocortin MC₃ receptor remains the most enigmatic of the melanocortin receptors with regard to its physiological functions. The receptor is expressed both in the CNS and in multiple tissues in the periphery. It appears to be an inhibitory autoreceptor on proopiomelanocortin neurons, yet global deletion of the receptor causes an obesity syndrome. Knockout of the receptor increases adipose mass without a readily measurable increase in food intake or decrease in energy expenditure. And finally, no melanocortin MC₃ receptor null humans have been identified and associations between variant alleles of the melanocortin MC₃ receptor and diseases remain controversial, so the physiological role of the receptor in humans remains to be determined.     

Occurrence of aflatoxin M1 in some samples of UHT,raw & pasteurized milk from Indian states of Karnataka and Tamilnadu

Aflatoxin M₁ (AFM₁) is a toxic metabolite found in the milk of lactating animals which have consumed feedstuffs contaminated with aflatoxin B₁. Ultra high temperature treated (UHT) milk is a product which is becoming popular in developing countries like India as there is a lack of proper cold storage or refrigeration facilities. In this study, 45 samples of UHT milk of popular brands prevalent in the market were analyzed for the presence of AFM₁ by reversed phase HPLC using fluorescent detector after cleanup of sample with immunoaffinity columns. All samples of plain UHT milk were positive for AFM₁ and 38% of these contained levels more than 0.5 μg/kg, the maximum permitted limit prescribed by the Codex Alimentarius Commission and by the mandatory regulations of the country, the FSSAI Regulations, 2011. In 62.5% of flavored UHT milk, AFM₁ was below detectable levels (0.02 μg L⁻¹). However, 12.5% of these samples also contained levels exceeding the maximum permitted limits. AFM₁ was present in 61.6% of the 52 raw milk samples analyzed from the two states of Karnataka and Tamilnadu with a range of 0.1–3.8 μg L⁻¹. 17.3% of these samples also exceeded the regulatory limits of the country.     

AC-260584, an orally bioavailable M1 muscarinic receptor allosteric agonist, improves cognitive performance in an animal model

The recent discovery of allosteric potentiators and agonists of the muscarinic M₁ receptor represents a significant advance in the muscarinic receptor pharmacology. In the current study we describe the receptor pharmacology and pro-cognitive action of the allosteric agonist AC-260584. Using in vitro cell-based assays with cell proliferation, phosphatidylinositol hydrolysis or calcium mobilization as endpoints, AC-260584 was found to be a potent (pEC₅₀ 7.6-7.7) and efficacious (90-98% of carbachol) muscarinic M₁ receptor agonist. Furthermore, as compared to orthosteric binding agonists, AC-260584 showed functional selectivity for the M₁ receptor over the M₂, M₃, M₄ and M₅ muscarinic receptor subtypes. Using GTPγS binding assays, its selectivity was found to be similar in native tissues expressing mAChRs to its profile in recombinant systems. In rodents, AC-260584 activated extracellular signal-regulated kinase 1 and 2 (ERK1/2) phosphorylation in the hippocampus, prefrontal cortex and perirhinal cortex. The ERK1/2 activation was dependent upon muscarinic M₁ receptor activation since it was not observed in M₁ knockout mice. AC-260584 also improved the cognitive performance of mice in the novel object recognition assay and its action is blocked by the muscarinic receptor antagonist pirenzepine. Taken together these results indicate for the first time that a M₁ receptor agonist selective over the other mAChR subtypes can have a symptomatically pro-cognitive action. In addition, AC-260584 was found to be orally bioavailable in rodents. Therefore, AC-260584 may serve as a lead compound in the development of M₁ selective drugs for the treatment of cognitive impairment associated with schizophrenia and Alzheimer's disease.